New abacavir data open door to a better treatment paradigm.
D000273:Adipose Tissue / Q000473:pathology; D019380:Anti-HIV Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D004342:Drug Hypersensitivity; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D010349:Patient Compliance; D010353:Patient Education as Topic; D012367:RNA, Viral / Q000097:blood; D019562:Viral Load; D000099227:Abacavir
D019380:Anti-HIV Agents; D015224:Dideoxynucleosides; D004338:Drug Combinations; D015507:Drugs, Investigational; D017320:HIV Protease Inhibitors; D012367:RNA, Viral; D000099227:Abacavir